European firms beat U.S. on drug access for poor
LONDON (Reuters) - European drugmakers are better than their U.S. counterparts in ensuring medicines reach people in poor countries, with Britain's GlaxoSmithKline Plc leading the field, according to an analysis on Monday.
<p><img src="http://feeds.reuters.com/~a/reuters/healthNews?i=0zPj6H" border="0"></img> (http://feeds.reuters.com/~a/reuters/healthNews?a=0zPj6H)</p><div class="feedflare">
<img src="http://feeds.reuters.com/~f/reuters/healthNews?i=hHFBmI" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=hHFBmI) <img src="http://feeds.reuters.com/~f/reuters/healthNews?i=9VcT4i" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=9VcT4i) <img src="http://feeds.reuters.com/~f/reuters/healthNews?i=lhRqyi" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=lhRqyi)
</div><img src="http://feeds.reuters.com/~r/reuters/healthNews/~4/312907598" height="1" width="1"/>
http://feeds.reuters.com/~r/reuters/healthNews/~3/312907598/idUSL1672114020080616